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Prostacyclins are routinely used to treat vascular features of systemic sclerosis (SSc, scleroderma) but require 
parenteral infusion or inhalation. This study evaluated the safety and efficacy of oral treprostinil in digital ulcers 
secondary to SSc. 
Methods: This was a randomized (1:1) placebo-controlled, multicenter study in adults with SSc and at least one 
active digital ulcer at entry. Oral treprostinil was administered twice daily and titrated to maximum tolerated dose 
with clinical assessments at Weeks 5, 10, 15 and 20. The primary endpoint was change in net digital ulcer burden. 
Secondary outcomes included ulcer healing and prevention, measures of hand function, quality of life, Raynaud 
phenomenon and global assessments. Simplified data were gathered during open-label follow up. 
Results: Enrolled were 147 patients (109F/38M), mean age 48.8 years with SSc of mean duration 10.5 years.   At 
week 20, mean net ulcer burden was reduced -0.43 ulcers on treprostinil (1.80 vs. 1.37) and -0.10 ulcers on placebo 
(1.61 vs. 1.51; p = 0.20). There were no effects on ulcer healing or prevention, and small, inconsistent effects on 
Raynaud phenomenon, global assessment, hand function and quality-of-life measures. In open-label follow-up, there 
was a continued, small reduction in net ulcer burden (-0.52 month 3, n = 104; -0.64 month 12, n = 36). Common 
adverse effects were headache, nausea, diarrhea, jaw pain, flushing and other gastrointestinal symptoms. 
Conclusions: Administration of oral treprostinil twice daily over 20 weeks was associated with small and statisti- cally 
insignificant reduction in net ulcer burden in comparison to placebo. 





Raynaud phenomenon and the related consequence of digital tip ulcers are a serious problem in many patients with 
systemic sclerosis (SSc, scleroderma) (1). Endoluminal change with intimal hyperplasia and medial/adventitial 
fibrosis are distinct facets of SSc vasculopathy resulting in impaired affer- ent perfusion as a contributing mechanism 
(2). Other factors include local platelet activation, leukocyte adherence, micro- vascular distortion and impaired 
efferent blood flow (1-3). 
Digital ulceration occurs in the clinical setting of episodic and reversible vasospasm and is thus thought to be 
amenable to anti-vasoconstrictive therapy. Prostacyclins have demon- strated efficacy as vasodilators for vascular 
features of SSc but systemic delivery requires parenteral infusion. Intravenous epoprostenol and iloprost and 
subcutaneous treprostinil have all been associated with healing of existing digital ulcers (4-6). Treprostinil diolamine 
is a salt form of the prostacyclin analogue treprostinil developed for oral administration as an extended-release 
osmotic tablet. Oral treprostinil is a licensed therapy for WHO Group 1 pulmonary arterial hypertension (PAH) 
including that developing as a complication of SSc (7, 8). A pilot trial in SSc patients with digital ulcers revealed 
improve- ment in digital perfusion and temperature in relation to plasma concentrations of oral treprostinil (9). 
The present study was designed to investigate the effects of oral treprostinil in comparison to placebo as a 
treatment for digital ulcers secondary to SSc over a 20-week period. The primary objective was change in net ulcer 
burden at Week 20. Secondary endpoints included patient ratings of pain, physi- cian and patient global  
assessments,  Raynaud  symptoms by visual analog scale (VAS), “cardinal” ulcer healing, pre- vention of new ulcers, 
and measures of hand function and quality of life. 
 Patients and methods 
Study design 
This double-blind, randomized, parallel group, placebo- controlled study consisted of a screening period not greater 
than 28 days and a 20-week treatment period. This study was approved by local ethics committees and conducted in 
ac- cordance with the ethical principles that have their origins in the Declaration of Helsinki and the International 
Conference on Harmonization E6 Good Clinical Practice guidance. All patients gave written informed consent. 
 Setting and participants 
Recruitment of 150 patients was planned. Male and fe- male patients with SSc, as defined by preliminary American 
College of Rheumatology criteria (10) who were at least 18 years of age and had the presence of at least one 
designated active digital ulcer at baseline were eligible. 
A digital ulcer was defined as an area with visually dis- cernable depth and a loss of continuity of epithelial cover- 
age, which could be denuded or covered by a scab or necrotic tissue. If the area was denuded, the ulcer was 
designated ac- tive. If denudation could not be judged because of the pres- ence of overlying scab or necrotic tissue, 
ulcers presenting with features, including underlying pain, based on investiga- tor clinical judgment to be consistent 
with loss of epitheliali- zation, epidermis, or dermis, and requiring treatment, were designated as active. Otherwise, 
the ulcer was categorized as indeterminate. These definitions did not include fissures, paronychia, extrusion of 
calcium, or ulcers over the metacar- pophalangeal joints or elbows. Only digital ulcers distal to the proximal 
interphalangeal joints, volar to the equator of the finger (inclusive of ulcers located on or crossing the median), and 
not localized in the proximal or distal interphalangeal creases, painful, possibly triggered by trauma, and without 
bone infection or subtending calcinosis were assessed. These features identified lesions presumed to be vascular in 
origin. Patients with known PAH or receiving bosentan were ex- cluded. Conventional therapy for SSc, Raynaud 
phenomenon and digital ulcers, if applicable and not otherwise prohibited by the entry criteria or explicitly 
prohibited by the protocol, was permitted to be continued without changes unless medi- cally warranted over the 
course of the study for all patients. Initially prohibited, the protocol was amended during the study to allow 
background phosphodiesterase-type 5 inhibi- tor (PDE5I) therapy, provided such treatment had been start- ed at 
least six months prior to baseline assessments (except for intermittent treatment of male erectile dysfunction) and 
continued throughout the study. The rationale was that the development of an active digital ulcer in the face of 
conventional therapy represented treatment failure. 
Other exclusion criteria included body weight <40 kg; his- tory of postural hypotension, unexplained syncope, a 
systolic blood pressure <90 mmHg; hemoglobin concentration <75% of the lower limit of the normal range; 
moderate to severe he- patic impairment, intractable diarrhea, or severe malabsorp- tion, defined >15% 
unintentional loss of bodyweight in the last 6 months prior to screening; any severe organ failure (e.g.,lung, kidney), 
bleeding diathesis or platelet disorder, or any life-threatening condition; pregnancy or breast-feeding; clinical 
diagnosis of SSc in overlap with another connective tissue dis- ease. Exclusions relevant to assessment of digital ulcer 
status included sympathectomy of the upper limb, including involv- ing the hand, performed within 12 months of 
baseline; receipt of prostanoid treatment (epoprostenol, treprostinil sodium, or other prostacyclin analogue) within 
the previous 3 months of baseline for conditions including Raynaud phenomenon, rest pain and/or digital ulcers; 
requirement for systemic antibiotics for infected digital ulcers within 2 weeks of screening; local injection of 
botulinum toxin in an affected finger or treatment with endothelin receptor antagonists within 1 month prior to 
baseline; treatment with statin within 1 month prior to screen- ing, unless for management of hyperlipidemia; and 
tobacco  or nicotine use at any level within the past 6 months prior to screening. 
 
Randomization and interventions 
Patients were randomized in a 1:1 ratio (active and place- bo) according to a centrally administered stratified 
permuted block randomization, stratified by number of active ulcers at baseline (≤2 ulcers and >2 ulcers). 
Background PDE5I therapy use was added as a stratum following protocol amendment. 
Patients were instructed to take study drug twice daily (BID; approximately every 12 ± 1 hours) with a meal 
containing approximately 500 calories. Dosing was initiated at 
0.25 mg BID and titrated gradually in stepwise 0.25 mg BID increments approximately every 48-72 hours to a 
maximum dose of 16 mg BID. Upon reaching a dose of 5 mg BID, the dose titration increment could be increased to 
0.5 mg BID every 48-72 hours at the investigator’s discretion. Dose esca- lation was suspended or the titration 
slowed at the investiga- tor’s discretion based upon individual patient tolerability. 
 
Outcomes 
The primary objective of this study was to assess the effi- cacy of oral treprostinil in reducing net ulcer burden. 
Second- ary endpoints included development of new ischemic digital ulcers, healing of a designated  cardinal  ulcer,  
assessment of digital ulcer-related pain, measures of patient and hand function (as Scleroderma Health Assessment 
Questionnaire [SHAQ]) and Cochin Hand Function Score (CHFS) (11), quality of life (via SF-36), patient and physician 
global assessment of digital ulcers measured via VAS. Patient impression of change (PIC) questionnaire and skin 
thickening assessed via the mod- ified Rodnan skin score (mRSS). Patients were assessed at baseline and at weeks 5, 
10, 15, and 20. 
One digital ulcer was identified and designated by the in- vestigator as the cardinal ulcer at baseline. The cardinal 
ulcer must have met the qualifications for designation as an ac- tive ulcer. If only one active ulcer was present at 
entry, it was designated as the cardinal ulcer. If several digital ulcers quali- fied, the cardinal ulcer could be either the 
largest or the most painful ulcer, or the ulcer that disturbed the patient the most. At each subsequent visit, the 
status of each digital lesion was rated as ‘active’, ‘healed’, or ‘indeterminate’. New digital ul- cers were recorded at 
each visit as well. 
  
Statistical methods 
The primary efficacy analysis compared change from baseline in net ulcer burden at Week 20 between treat- ment 
groups in the intention to treat (ITT) population using nonparametric analysis of covariance within the framework of 
the extended Cochran-Mantel-Haenszel test. Net ulcer burden was calculated as all baseline “active” ulcers (unless 
graded “healed”) + all new ulcers (unless graded “healed”). Indeterminate” ulcers at baseline were not counted 
unless they became “active” during the study. Specifically, a Cochran-Mantel Haenszel mean score test was used on 
the standardized reverse mid-ranks (i.e., overall reverse ranks divided by the number of ranks + 1, or “modified ridit” 
scores; thus, largely negative changes had ranks near 1 and largely positive changes had ranks near 0) of the 
residuals from an ordinary least-squares regression with change in net ulcer burden at Week 20 as a linear function 
of baseline PD5EI or prostacyclin use (as a binary variable: Yes or No) and net ulcer burden at baseline (as a 
continuous variable). The magnitude of the treatment effect was assessed with the median difference between 
treatment groups as determined by the Hodges-Lehmann (H-L) estimate. For missing primary efficacy data and 
parametric analyses, missing values were imputed using a value corresponding to the mean of the changes in all 
observed values from their respective baseline across all observed values in the placebo group for that assessment. 
For all nonparametric analyses, patients who did not meet the criteria for being assigned the lowest rank had their 
standardized rank imputed using the mean placebo rank (i.e., arithmetic mean of all observed ranks in the placebo 
group for that assessment). 
Measures of ulcer healing were included as secondary outcomes. A patient’s cardinal ulcer was considered 
completely healed at the earliest assessment for which it was designated as “healed”. A patient was counted as 
having all ulcers completely healed at the earliest assessment for which all ulcers were designated as “healed” and 
after which no new ulcers were recorded for the remainder of the trial. The time to complete healing of the cardinal 
ulcer and all ulcers was calculated as the number of days from randomiza- tion to the date of these respective 
assessments, provided that complete healing was achieved during the study. Actual healing times, censoring times, 
and disease progression and mortality information was incorporated into a single ranked response score for each 
patient for both the cardinal ulcer and all ulcers as specified in the statistical analysis plan. Stan- dardized mid-ranks 
(or “modified ridit” scores) of the time to healing rank scores were calculated. The standardized mid-ranks were 
compared between treatment groups using log-rank test. The number and percentage of patients who developed 
new ulcers during the study were summarized and rates between treatment groups were compared using the 
Fisher’s exact test. 
The digital ulcer VAS-pain assessment was captured in millimeters, with possible values ranging from 0 to 100. The 
recorded value was divided by 10, with values ranging from 
0.0 (no pain) to 10.0 (unbearable pain), expressed to one dec- imal point. The patient and physician VAS-global 
assessments were recorded in centimeters, with possible  values ranging 
  
 




from 0.0 to 15.0. The recorded value was divided by 15, then multiplied by 100 to convert it to the VAS-global scale, 
with values ranging from 0 (no disease activity) to 100 (very severe disease). The difference between treatment 
groups for the change from baseline VAS at each assessment was tested us- ing the Wilcoxon rank-sum test. 
Component, domain and aggregate scores were calculat- ed according to the designated scoring tools for the SF-
MPQ, CHFS, SHAQ and SF-36 (SF-36v2 scoring manual) question- naires and the difference between treatment 
groups for the change from baseline for each component at each assess- ment was tested using the Wilcoxon rank-
sum test. 
The PIC assessments (for digital ulcers, Raynaud symp- toms, and overall) have possible integer values ranging from 
-3 (very much worse) to +3 (very much improved). The differ- ence between treatment groups for the change from 
baseline at each assessment was tested using the Wilcoxon rank-sum test. Assessment of Raynaud phenomenon 
was, by design, limited in this study. Impact of treatment on Raynaud phemomenon was assessed via the 
Scleroderma Specific Rayn- aud Visual Analogue Scale subcomponent of the SHAQ. The difference between 
treatment groups for the change from baseline at each assessment was tested using the Wilcoxon rank-sum test. 
The difference between treatment groups for the change from baseline and at Week 20 in the mRSS was tested 
using the Wilcoxon rank-sum test. 
Sample size calculations were based on the RAPIDS-2 trial (12) during which the background rate in overall mean 
change in digital ulcers was approximately -1.5 (standard deviation [SD] = 3) at 5 months. Using an allocation ratio of 
1:1 between oral treprostinil and placebo, a fixed sample size of 128 patients provided 80% power to detect a be- 
tween-treatment difference at a significance level of 0.05 (two-sided hypothesis) assuming the active group leads to   
a change of -3 digital ulcers. Drop-out rate was estimated   to be 10%-15%; therefore, enrollment of approximately 
150 patients was planned to account for additional variability from imputation. 
 
Results 
Patient characteristics and disposition 
One hundred and forty-eight patients were enrolled and randomized with 147 patients (71 active/76 placebo) 
receiv- ing at least one dose of study drug; one patient withdrew consent after randomization prior to taking any 
study medi- cation. The disposition of patients is illustrated in Figure 1. 
Patient demographics and disease characteristics were typical for recent studies of SSc-related Raynaud phenome- 
non or digital ulcers, dominantly female with limited cutane- ous SSc of long duration (mean 10 years). The two 
treatment groups were well matched for the number of active ulcers and total ulcers at study entry (Tab. I). 
The mean ±SD maximum dose of oral treprostinil at Week 20 was 3.25 ± 2.8 mg BID (range, 0-13 mg) compared with 
8.13 ± 4.9 mg BID (range, 0-16 mg) in the placebo group. Doses of treprostinil versus placebo reached at Week 5, 10 
and 15 were 2.27 ± 0.96 mg versus 2.70 ± 1.04 mg; 3.35 ± 
2.25 mg versus 5.24 ± 2 mg; and 3.49 ± 2.80 mg versus 7.79 ± 
3.46 mg, respectively. 
 
Primary outcome – net ulcer burden 
The primary hypothesis of this trial was that oral trepro- stinil would reduce the net ulcer burden in comparison to 
placebo at Week 20 in patients with SSc. Table II summa- rizes the mean net ulcer burden and change from baseline 
for each visit in the ITT primary analysis population. Whereas the reduction of -0.37 ulcers after 15 weeks of oral 
trepro- stinil versus an increase of 0.07 net ulcers on placebo was statistically significant (p = 0.05), results at 20 
weeks were not ulcer burden (e.g., 20%, 30%, 40% and 50%). There was no relationship of response to background 
therapy including use of PDE5Is, SSc disease classification and autoantibody status. Only 13% of patients in the study 
population had greater than two active ulcers documented at the time of baseline limiting evaluation of a treatment 
effect based on disease severity. Treatment effect was not associated with increasing exposure (dose) to oral 
treprostinil therapy. However, dose response was not a planned endpoint in this study; therefore, formal dose-
response analyses were not planned. Utilization of a ti- trated dosing regimen, based on patient tolerability, provides 








Net ulcer burden would be influenced by healing of exist- ing ulcers and by prevention of the occurrence of new 
digital ulcers. There was no difference in proportion of patients re- porting complete healing of the cardinal ulcer, all 
ulcers, or in time to healing observed between treatment groups. The proportion of patients with no new digital 
ulcers up to Week 20 was similar with oral treprostinil and placebo (Tab. III). The maximum number of new digital 
ulcers per patient was six for both treatment groups. 
 
Other outcomes 
Statically significant reductions in digital ulcer pain VAS were reported at Week 10 and 15; however, while a clini- 
cally relevant reduction was observed on active treatment at Week 20 (median change -1.45 on treprostinil; -0.40 on 
placebo), the between treatment differences were not sig- nificant (H-L treatment effect estimate = -0.4 [95% CI -
1.40, 0.40]; p = 0.31). Digital ulcer pain was also assessed using the Short-Form McGill Pain questionnaire  and  there  
was no observed treatment effect on any of the component scores. 
  
 
 Safety and tolerability 
Seventy-one patients (100%) in the active treatment group and 74 patients (97%) in the placebo treatment group 
report- ed at least one adverse effect (AE), regardless of relationship during the course of the study. Overall, the 
most commonly reported AEs considered probably or possibly related to oral treprostinil that occurred more 
frequently in the active group were headache (73%), nausea (56%), diarrhea (52%), flush- ing (24%), pain in jaw 
(23%) and vomiting (17%); these same events occurred in 37%, 14%, 16%, 3%, 5% and 1% of placebo patients, 
respectively. The majority of AEs in the two groups were reported to be either mild or moderate in intensity. 
Headache was the most frequent AE attributed to study drug and was rated as severe in 10% of active patients 
compared to 1% of placebo patients. These are expected effects of sys- temic prostacyclin therapy. Overall, there 
was no difference in the number of patients in the active (11 patients) or placebo (eight patients) treatment groups 
who reported permanently discontinuing the study drug due to AEs. 
A total of 27 serious adverse events were reported by thirteen patients  (active:  9  patients,  22  events;  placebo: 4 
patients, 5 events) during the study. Six events in the ac- tive treatment group were considered probably or possibly 
attributable to study drug. There were no deaths  during this trial. 
Open-label follow-up 
Patients completing the full 20 weeks of the randomized phase of trial were offered open-label treatment with oral 
treprostinil according to the same titration schedule. This continued until the randomized phase of study was 
complet- ed with analysis of results. Study visits were at one month, then every three months and included 115 
patients. 
A decrease in net ulcer burden and total ulcer number was observed and persisted over the duration of the study 
(Tab. V). No new ulcer formation was reported in 48 (42%) pa- tients; with 63 (55%) reporting at least one new ulcer 
during the duration of the study. An average of 1.52 new ulcers per patient-year of follow-up developed during the 
study. 
 Discussion 
This randomized, placebo-controlled trial failed to achieve the a priori specified primary endpoint of a reduction in 
net ulcer burden at 20 Weeks. Post hoc analysis evaluating change in total ulcers was also not significant. 
Additionally, no sig- nificant treatment effect was observed at Week 20 in several secondary outcomes, including 
ulcer healing, ulcer pain, pa- tient rating of disease severity, CHFS and SF-36 questionnaire. Interestingly, at 15 
Weeks, there was a statistically significant reduction in net ulcer burden, as well as, improvement in the Grip and 
Hand Function components of the SHAQ, pa- tient and physician global assessment, ulcer pain and patient ratings of 
Raynaud phenomenon. Physician-rated digital ul- cer disease severity VAS-global scores remained significant at 
Week 20, but were discordant with the net ulcer burden outcome and patient VAS scores for pain and digital ulcer 
se- verity. There were significant differences in patient percep- tion with positive improvements in Raynaud 
phenomenon symptoms (p = 0.00004) and how they felt overall (p = 0.02) between treatment groups on the PIC 
questionnaire at Week 
20. The open-label extension showed a similar small effect of continuing therapy with a reduction in net ulcer 
burden at 9 months of -0.52 ulcers. 
We had hypothesized that the approach of a maximally tolerated dosing scheme would permit full realization of po- 
tential therapeutic effects of systemic prostanoids. A previous trial with a fixed low dose of oral iloprost for Raynaud 
phe- nomenon secondary to SSc had failed to demonstrate ben- efit (13) in contrast to effects seen with maximum 
tolerated dosing by intravenous administration (14). Dose response in prostacyclin therapy is inherent in the clinical 
use in PAH (4, 7, 8, 15). It is possible that our dosing schedule was inappropri- ate. Although the trials supporting 
registration of oral trepro- stinil for PAH were also conducted on a BID dosing schedule (7, 8), three times a day (TID) 
dosing has been shown to pro- vide a sustained plasma exposure at steady state in normal volunteers (16). Limited 
study of TID dosing in patients with PAH has demonstrated improved efficacy and tolerability as well as a reduced 
peak:trough ratio of plasma treprostinil levels (17). It is possible that TID dosing in patients with digi- tal ulcers 
secondary to SSc might lead to a larger clinical ef- fect. It is also possible that longer duration of therapy would make 
a difference; particularly given the significant structural vascular disease present in scleroderma. While not achiev- 
ing statistical significance, we note a trend of continuous im- provement in net ulcer burden whilst on oral 
treprostinil both during the controlled and open-label phases of this study. 
Accepting this trial as offering no evidence of therapeutic effect does not exclude consideration of other potential 
rea- sons for failure. The vascular damage in the fingers of patients with SSc is notable for its irregular distribution. 
Studies by high-resolution magnetic resonance angiography have sug- gested that the digits in which ulcerations 
develop have more severe vascular attenuation (18). Improving proximal blood flow may not be sufficient to address 
the biology of critical tissue ischemia in this clinical setting. These conclusions are similar to those seen in studies of 
peripheral vascular disease of the lower extremity wherein gains seen in intermittent claudication are not paralleled 
by reduction in need for surgi- cal amputation (19). Effective vasodilatation may represent an inadequate treatment 
for this common clinical problem. 
Two randomized controlled trials with bosentan demon- strated an effect in reducing the occurrence of new digital 
ulcers with effects most easily demonstrated in patients with higher numbers of ulcers at trial outset (12, 20). 
Neither trial demonstrated effects on ulcer healing or on overall net ulcer burden and was thus not associated with 
improved patient hand function. Treatment effects were not seen in Raynaud phenomenon. These trials suggest a 
more subtle effect on peripheral vascular integrity or angiogenesis. High levels of pla- cental growth factor and low 
circulating endothelial progeni- tor cells have been associated with the occurrence of digital ulcers in SSc (21). 
Emerging data suggest benefits of bone- marrow-derived mononuclear cell implantation in the treat- ment of SSc 
patients with ischemic ulcers of the digits (22). 
The primary endpoint of this trial required investigator clinical judgment as to whether or not a digital lesion was   in 
fact an ulcer and furthermore required serial judgment   as to “active” versus “indeterminant” versus “healed”. One 
web-based study of photographs of SSc-related digital le- sions suggested that intra-observer reliability was quite 
high (kappa value of 0.81), but that inter-observer consistency was strikingly weak (kappa = 0.46) (23). We utilized 
iterative pho- tographic examples in investigator training sessions, but did not have a mechanism to test-retest 
investigator consistency during the period of trial performance. It remains possible that clinical inconsistency in 
scoring digital lesions was a fac- tor in diminishing the capability to judge therapeutic effect. However, the lack of 
other validated measures of outcome in paralleling ulcer counts suggests that this was not an impor- tant factor. 
In summary, this placebo-controlled trial of oral treprosti- nil, using a maximum-tolerated BID dose schedule, failed 
to demonstrate benefit in patients with digital ulcers secondary to systemic sclerosis. 
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taBle ii - Summary of mean net ulcer burden and mean change from baseline in ITT population 
time period net ulcer burden 
Oral treprostinil n = 71 Placebo n = 76 
 Mean ± sD Mean change from 
baseline 
Mean ± sD Mean change from 
baseline 
Baseline 1.80 ± 1.13  1.61 ± 0.87  
Week 5 1.80 ± 1.23 -0.00 ± 1.10 1.56 ± 0.97 -0.04 ± 0.87 
Week 10 1.53 ± 1.50 -0.27 ± 1.55 1.48 ± 1.17 -0.12 ± 1.15 
Week 15 1.44 ± 1.83 -0.37 ± 1.72 1.67 ± 1.65 0.07 ± 1.65 
Week 20 1.37 ± 1.85 -0.43 ± 1.83 1.51 ± 1.79 -0.10 ± 1.81 




taBle iV - Summary of magnitude of effect from baseline to week 20 in SHAQ domain scores 
 
component shaQ component score Median Hodges-Lehmann estimate of 




Oral treprostinil n = 71 Placebo n = 76 
 Baseline Week 20 Baseline Week 20  
Dressing and grooming 1.00 0.50 0.50 0.50 0.00 (0.00, 0.00) 0.11 
Arising 0.00 0.00 0.00 0.00 0.00 (0.00, 0.00) 0.71 
Eating 0.67 0.67 0.67 0.67 0.00 (-0.33, 0.00) 0.15 
Walking 0.00 0.00 0.00 0.00 0.00 (0.00, 0.00) 0.35 
Hygienea 0.33 0.33 0.00 0.00 0.00 (0.00, 0.00) 0.80 
Reacha 0.50 0.50 0.00 0.50 0.00 (0.00, 0.00) 0.76 
Gripa 0.33 0.33 0.33 0.33 0.00 (-0.33, 0.00) 0.05 
Activitya 0.67 0.33 0.33 0.33 0.00 (0.00, 0.00) 0.37 
HAQ aggregate scorea 0.53 0.48 0.34 0.43 -0.06 (-0.13, 0.00) 0.06 
Hand function aggregate scorea 0.57 0.50 0.39 0.42 -0.11 (-0.17, 0.00) 0.05 
Intestinal problems VASb 0.11 0.47 0.20 0.30 0.10 (0.00, 0.30) 0.06 
RP VASc 0.18 0.14 0.12 0.14 0.00 (-0.06, 0.06) 0.81 
Digital ulcer VAS 1.50 0.50 1.43 0.77 -0.18 (-0.50, 0.06) 0.13 
Breathing problems VAS 2.16* 0.34 1.54* 0.78 -0.42 (-0.76, -0.10) 0.01 
Pain VASd 1.54 0.54 1.27 0.75 -0.24 (-0.52, 0.02) 0.07 
Overall disease VAS 1.52 1.06 1.22 0.87 -0.12 (-0.38, 0.14) 0.39 
§ Wilcoxon sum-rank test. 
* p<0.05. 
a Treprostinil n = 68/placebo, n = 76. 
b Treprostinil, n = 70/placebo, n = 75. 
c Treprostinil, n = 71/placebo, n = 75. 
d Treprostinil, n = 69/placebo, n = 76. 
SHAQ = Scleroderma Health Assessment Questionnaire; VAS = visual analog scale; HAQ = Health Assessment Questionnaire; RP = Raynaud phenomenon. 
  
 
